Abstract
Patients (pts) with T-NHL have a poor prognosis with standard chemotherapy. HSCT have been used in their management but the most appropriate time for HSCT is not clear. We previously reported the poor outcome of pts with ALK negative (anaplastic lymphoma kinase) anaplastic large cell lymphoma (ALCL) having HSCT after first recurrence (Zamkoff et al, BMT 33:635-8,2004). To further investigate outcomes of pts transplanted for T-NHL, we retrospectively analyzed 33 pts undergoing autologous HSCT from August 2000 to July 2009.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
